Predict your next investment

Family Office
jagen.com.au

See what CB Insights has to offer

Investments

2

About Jagen Group

The Jagen Group is one of the investment vehicles of the Liberman family.

Jagen Group Headquarter Location

Melbourne, Victoria,

Australia

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Jagen Group News

Enlitic Closes $25 Million in Series B-1 Funding Round

Nov 25, 2019

New Equity Capital Fuels Momentum as Company Sets Its Sights on Market Deployment in 2020, Lawrence Gozlan Joins Board of Directors Enlitic, Inc. , a leading developer of artificial intelligence (AI) software designed to help doctors diagnose patient conditions more quickly and more accurately, announced the completion of $25 million in Series B-1 financing. Thorney Investment Group, one of Australia’s leading investment groups, led the round and Enlitic’s existing investors Capitol Health, Marubeni Corporation, Amplify Partners, The Jagen Group, and Regal Funds Management – also participated. Enlitic will use the proceeds for the next phase build-out of its comprehensive AI software platform and to further grow its global footprint with major regional partners in the healthcare industry, paving the way for market deployment in 2020. The company will debut its new platform in December at RSNA 2019. Enlitic also announced the appointment of Lawrence Gozlan of The Jagen Group to the company’s board of directors, joining Sunil Dhaliwal of Amplify partners, Andrew Harrison of Capitol Health, Kevin Lyman, Enlitic’s Chief Executive Officer, and Michael Sistenich, Enlitic’s Chairman of the Board. In building the company’s best-in-class platform, Enlitic’s team of practicing radiologists, data scientists, and software engineers analyze millions of clinical cases from global healthcare partners to improve diagnostic accuracy, speed, and patient outcomes, as well as to accelerate pharmaceutical research and drug trials. Since undergoing an executive reorganization in June of 2018 that included the appointment of Kevin Lyman as Chief Executive Officer, Anthony Upton as Chief Medical Officer, and Michael Sistenich as Chairman of the Board, Enlitic has experienced unprecedented growth that includes the following achievements: In April, Enlitic announced that it had completed its Series B funding with a $15 million raise. Also, in April, the company signed a significant joint development agreement with Marubeni Corporation and global imaging company, Konica-Minolta, that streamlines Enlitic’s expansion efforts in the Asian market. In August, Enlitic announced that it had rounded out its core leadership team by appointing a Chief Financial Officer and heads of Research & Development, Business Development, Regulatory & Quality Assurance, Creative, and Communications. The company also opened a new office in New York City. In October, the company announced a partnership with Select Healthcare Solutions, a healthcare technology and services provider that owns and operates cancer centers across the U.S. The partnership provides Enlitic with high-quality data to accelerate its research into the early detection of most forms of cancer and will help drive the company’s development of best-in-class workflow solutions for oncology centers around the world. “Enlitic’s rapid growth, including our successful fundraising, points to the enthusiasm and confidence we have elicited in the marketplace with the development of our comprehensive AI software platform and our highly efficient business model,” said Kevin Lyman , Enlitic’s Chief Executive Officer. “We look forward to formally debuting our platform at RSNA 2019 in December and to its market deployment in 2020.” Alex Waislitz, Founder and Chairman of Thorney Investment Group said, “The global healthcare industry is experiencing the dawn of a new age with artificial intelligence and we are excited to be at its forefront with our investment in Enlitic and the company’s game changing AI-powered software platform.” Commenting on the appointment of Lawrence Gozlan to Enlitic’s board of directors, Michael Sistenich, Enlitic’s Board Chairman said, “Lawrence joins us with one of the most extensive backgrounds in the biotechnology and healthcare investment communities. I am certain that his expertise and keen eye to the future of global healthcare will add tremendous value to our board.”

Jagen Group Investments

2 Investments

Jagen Group has made 2 investments. Their latest investment was in Enlitic as part of their Series B - II on November 11, 2019.

CBI Logo

Jagen Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/14/2019

Series B - II

Enlitic

$25M

Yes

5

11/29/2016

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/14/2019

11/29/2016

Round

Series B - II

Series A - II

Company

Enlitic

Subscribe to see more

Amount

$25M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

5

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.